Covid19_LndPg_bnr.Flex.v1 3

 

 

 

In response to the global outbreak of the novel coronavirus disease (COVID-19), Luminex has developed multiple solutions to enhance our NxTAG® and ARIES® offerings in order to automate and facilitate the detection of coronavirus.

As a high-throughput, more comprehensive option, we have developed the NxTAG® CoV Extended Panel (RUO), which can detect SARS-CoV-2, as well as SARS-CoV and MERS-CoV.

The NxTAG® CoV Extended Panel (RUO) was developed for use on the MAGPIX® System, and offers:

  • A highly scalable, cost-effective solution that can process up to 96 samples in approximately 4 hours.
  • SARS-CoV-2, SARS-CoV, and MERS-CoV detection, enabling comprehensive results.
  • The flexibility to run tests in any combination—use the NxTAG CoV panel as a standalone test for coronavirus detection, detect 21 other common respiratory pathogens with the NxTAG® Respiratory Pathogen Panel (RPP), or run both tests in parallel for a complete picture of respiratory health.

For more targeted coronavirus testing in moderate-complexity labs, the ARIES® SARS-CoV-2 Assay (RUO) is a sample-to-answer test that detects SARS-CoV-2 in nasopharyngeal swabs.

The ARIES® SARS CoV-2 Assay offers:

  • Precise Results: A moderate-complexity, sample-to-answer test that enables targeted SARS-CoV-2 detection.
  • Fast Turnaround Time: Minimal hands-on-time and an automated workflow delivers results in about 2 hours.
  • Robust Detection: Exonuclease-sensitive probes for the ORF1ab and N viral genes provide superior specificity.

Additionally, Luminex has LDT tools that can be used with the latest published primer sequences to detect SARS-CoV-2, enabling users to develop their own LDTs on the ARIES® sample-to-answer system. Using this approach, labs have already validated their own ARIES®-based, multi-target tests.

SARS-COVID-2 White Paper

A targeted SARS-CoV-2 LDT testing strategy using the ARIES® System offers:

  • Full Automation: A sample-to-answer test that enables targeted SARS CoV-2 detection.
  • Fast Turnaround Time: Minimal hands-on time and an automated workflow deliver results in about 2 hours.
  • Economical Design: Just insert your sample into the cartridge—extraction and amplification reagents are included.
  • Robust Detection: Exonuclease-sensitive probes for the ORF1ab and N viral genes provide exceptional specificity.

 

 

To learn more about Luminex's SARS-CoV-2 solutions outside of the EU, please check our
regional websites
(US, Japan, China).

 


Coronavirus (COVID-19) Press Releases

Luminex Receives FDA Emergency Use Authorization for ARIES® SARS-CoV-2 Assay
to Detect Virus Responsible for COVID-19 Disease
- April 6th

Luminex Receives BARDA Contract to Support Development of Second, Rapid SARS-CoV-2 Test - March 31st

Luminex Receives FDA Emergency Use Authorization for NxTAG® CoV Extended
Panel to Detect the SARS-CoV-2 Virus that Causes COVID-19 Disease
- March 27th

Luminex Provides Update on SARS-CoV-2 Validation Testing Efforts - March 13th

Luminex Provides Updates on Critical Efforts Related to Novel Coronavirus - March 4th


Speak with a Sales Representative

 

 

These products are for Research Use Only. Not for use in diagnostic procedures. Please contact Luminex at support@luminexcorp.com to obtain the appropriate product information for your country of residence.

©2020 Luminex Corporation. All rights reserved.